Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
The FDA's Fast Track designation program is intended to facilitate and expedite the development and review of new drugs in the U.S. for the treatment of a serious or life-threatening condition.
PYX-201 is currently being evaluated in multiple Phase 1 studies in various types of solid tumors.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.